Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ascendis Pharma A/S (ASND) vs Novartis AG (NVS) Price & Performance

Ascendis Pharma A/STrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

Ascendis Pharma A/S vs Novartis AG — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.67B), while Novartis AG trades at $152.33 (market cap $295.37B). The key difference: Novartis AG is far larger — about 17.7× Ascendis Pharma A/S's market cap, and Novartis AG pays a 3.07% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.

ASNDNVS
Market Cap
$16.67B$295.37B
Sector
HealthHealth
52-Week High
$277.18$168.62
52-Week Low
$189.74$119.31
Enterprise Value
$17.04B$336.69B
Dividend Yield
3.07%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

Read more on ASND

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS